901 related articles for article (PubMed ID: 16129833)
61. ESCRT-III controls nuclear envelope deformation induced by progerin.
Arii J; Maeda F; Maruzuru Y; Koyanagi N; Kato A; Mori Y; Kawaguchi Y
Sci Rep; 2020 Nov; 10(1):18877. PubMed ID: 33139753
[TBL] [Abstract][Full Text] [Related]
62. Progerin sequestration of PCNA promotes replication fork collapse and mislocalization of XPA in laminopathy-related progeroid syndromes.
Hilton BA; Liu J; Cartwright BM; Liu Y; Breitman M; Wang Y; Jones R; Tang H; Rusinol A; Musich PR; Zou Y
FASEB J; 2017 Sep; 31(9):3882-3893. PubMed ID: 28515154
[TBL] [Abstract][Full Text] [Related]
63. Suppression of proliferative defects associated with processing-defective lamin A mutants by hTERT or inactivation of p53.
Kudlow BA; Stanfel MN; Burtner CR; Johnston ED; Kennedy BK
Mol Biol Cell; 2008 Dec; 19(12):5238-48. PubMed ID: 18843043
[TBL] [Abstract][Full Text] [Related]
64. Novel progerin-interactive partner proteins hnRNP E1, EGF, Mel 18, and UBC9 interact with lamin A/C.
Zhong N; Radu G; Ju W; Brown WT
Biochem Biophys Res Commun; 2005 Dec; 338(2):855-61. PubMed ID: 16248985
[TBL] [Abstract][Full Text] [Related]
65. Progerin reduces LAP2α-telomere association in Hutchinson-Gilford progeria.
Chojnowski A; Ong PF; Wong ES; Lim JS; Mutalif RA; Navasankari R; Dutta B; Yang H; Liow YY; Sze SK; Boudier T; Wright GD; Colman A; Burke B; Stewart CL; Dreesen O
Elife; 2015 Aug; 4():. PubMed ID: 26312502
[TBL] [Abstract][Full Text] [Related]
66. A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation.
Yang SH; Meta M; Qiao X; Frost D; Bauch J; Coffinier C; Majumdar S; Bergo MO; Young SG; Fong LG
J Clin Invest; 2006 Aug; 116(8):2115-21. PubMed ID: 16862216
[TBL] [Abstract][Full Text] [Related]
67. Protein farnesyltransferase inhibitors and progeria.
Meta M; Yang SH; Bergo MO; Fong LG; Young SG
Trends Mol Med; 2006 Oct; 12(10):480-7. PubMed ID: 16942914
[TBL] [Abstract][Full Text] [Related]
68. Molecular insights into the premature aging disease progeria.
Vidak S; Foisner R
Histochem Cell Biol; 2016 Apr; 145(4):401-17. PubMed ID: 26847180
[TBL] [Abstract][Full Text] [Related]
69. Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome.
Goldman RD; Shumaker DK; Erdos MR; Eriksson M; Goldman AE; Gordon LB; Gruenbaum Y; Khuon S; Mendez M; Varga R; Collins FS
Proc Natl Acad Sci U S A; 2004 Jun; 101(24):8963-8. PubMed ID: 15184648
[TBL] [Abstract][Full Text] [Related]
70. A conserved splicing mechanism of the LMNA gene controls premature aging.
Lopez-Mejia IC; Vautrot V; De Toledo M; Behm-Ansmant I; Bourgeois CF; Navarro CL; Osorio FG; Freije JM; Stévenin J; De Sandre-Giovannoli A; Lopez-Otin C; Lévy N; Branlant C; Tazi J
Hum Mol Genet; 2011 Dec; 20(23):4540-55. PubMed ID: 21875900
[TBL] [Abstract][Full Text] [Related]
71. Temsirolimus Partially Rescues the Hutchinson-Gilford Progeria Cellular Phenotype.
Gabriel D; Gordon LB; Djabali K
PLoS One; 2016; 11(12):e0168988. PubMed ID: 28033363
[TBL] [Abstract][Full Text] [Related]
72. The truncated prelamin A in Hutchinson-Gilford progeria syndrome alters segregation of A-type and B-type lamin homopolymers.
Delbarre E; Tramier M; Coppey-Moisan M; Gaillard C; Courvalin JC; Buendia B
Hum Mol Genet; 2006 Apr; 15(7):1113-22. PubMed ID: 16481358
[TBL] [Abstract][Full Text] [Related]
73. Eliminating the synthesis of mature lamin A reduces disease phenotypes in mice carrying a Hutchinson-Gilford progeria syndrome allele.
Yang SH; Qiao X; Farber E; Chang SY; Fong LG; Young SG
J Biol Chem; 2008 Mar; 283(11):7094-9. PubMed ID: 18178963
[TBL] [Abstract][Full Text] [Related]
74. Vascular smooth muscle cell loss underpins the accelerated atherosclerosis in Hutchinson-Gilford progeria syndrome.
Hamczyk MR; Andrés V
Nucleus; 2019 Dec; 10(1):28-34. PubMed ID: 30900948
[TBL] [Abstract][Full Text] [Related]
75. Assessing the efficacy of protein farnesyltransferase inhibitors in mouse models of progeria.
Yang SH; Chang SY; Andres DA; Spielmann HP; Young SG; Fong LG
J Lipid Res; 2010 Feb; 51(2):400-5. PubMed ID: 19965595
[TBL] [Abstract][Full Text] [Related]
76. Hutchinson-Gilford Progeria Syndrome: A premature aging disease caused by LMNA gene mutations.
Gonzalo S; Kreienkamp R; Askjaer P
Ageing Res Rev; 2017 Jan; 33():18-29. PubMed ID: 27374873
[TBL] [Abstract][Full Text] [Related]
77. A-type lamins and Hutchinson-Gilford progeria syndrome: pathogenesis and therapy.
Gonzalez JM; Pla D; Perez-Sala D; Andres V
Front Biosci (Schol Ed); 2011 Jun; 3(3):1133-46. PubMed ID: 21622261
[TBL] [Abstract][Full Text] [Related]
78. Transgene silencing of the Hutchinson-Gilford progeria syndrome mutation results in a reversible bone phenotype, whereas resveratrol treatment does not show overall beneficial effects.
Strandgren C; Nasser HA; McKenna T; Koskela A; Tuukkanen J; Ohlsson C; Rozell B; Eriksson M
FASEB J; 2015 Aug; 29(8):3193-205. PubMed ID: 25877214
[TBL] [Abstract][Full Text] [Related]
79. Splicing-directed therapy in a new mouse model of human accelerated aging.
Osorio FG; Navarro CL; Cadiñanos J; López-Mejía IC; Quirós PM; Bartoli C; Rivera J; Tazi J; Guzmán G; Varela I; Depetris D; de Carlos F; Cobo J; Andrés V; De Sandre-Giovannoli A; Freije JM; Lévy N; López-Otín C
Sci Transl Med; 2011 Oct; 3(106):106ra107. PubMed ID: 22030750
[TBL] [Abstract][Full Text] [Related]
80. Enhanced SRSF5 Protein Expression Reinforces Lamin A mRNA Production in HeLa Cells and Fibroblasts of Progeria Patients.
Vautrot V; Aigueperse C; Oillo-Blanloeil F; Hupont S; Stevenin J; Branlant C; Behm-Ansmant I
Hum Mutat; 2016 Mar; 37(3):280-91. PubMed ID: 26670336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
